These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15237854)

  • 1. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
    Yu AM; Idle JR; Gonzalez FJ
    Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
    Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
    Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
    Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
    Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
    Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
    Evert B; Eichelbaum M; Haubruck H; Zanger UM
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
    Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
    Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
    Wu C; Jiang XL; Shen HW; Yu AM
    Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
    Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
    Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
    Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
    Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines.
    Scheer N; Kapelyukh Y; McEwan J; Beuger V; Stanley LA; Rode A; Wolf CR
    Mol Pharmacol; 2012 Jan; 81(1):63-72. PubMed ID: 21989258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
    Miksys SL; Cheung C; Gonzalez FJ; Tyndale RF
    Drug Metab Dispos; 2005 Oct; 33(10):1495-502. PubMed ID: 16033950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
    Thuerauf N; Lunkenheimer J
    Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.